19-01-2024
20p (market cap £12m) doesn't seem an unreasonable valuation to me at this stage, and then grow from there as news flow continues in 2024, especially with NCI updates etc. If they need to raise a modest amount of cash for working capital at much higher valuations, I don't think any reasonable holder will object.
As the CEO has highlighted, once NCI endorsement/validation has been achieved in the next 12-18 months, the company becomes a glaring takeover target. £100m (150p per share) would be a very achievable valuation, quite possibly substantially more. £100m is small change to a major pharma!
While there's no doubt it's a risky AIM smallcap, on the positive side there seems to be little downside at a market cap of £4m?
Good luck all, no advice intended etc
28-11-2023
Testing s the limits. It seems you can still sell loads, and usually you get a lot less than the quoted price. It looks like all these sellers are just helping the huge buy order in the background. Most likely loading up for the possible takeover.